Previous 10 | Next 10 |
2023-07-11 08:50:31 ET Biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, Armata Pharmaceuticals ( NYSE: ARMP ) enters into a credit and security ...
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics PR Newswire Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned ...
Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy PR Newswire MARINA DEL REY, Calif. , May 31, 2023 /PRNewswire/ -- Armata Pharmaceuticals, In...
2023-05-18 07:30:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time to start the day with a breakdown of all the biggest pre-market stock movers worth reading about on Thursday! Moving stocks this morning are public offerings, earnings repo...
2023-05-11 17:46:10 ET Armata Pharmaceuticals press release ( NYSE: ARMP ): Q1 GAAP EPS of -$0.40. Revenue of $0.79M (-35.8% Y/Y). Cash and Equivalents. As of March 31, 2023, Armata held approximately $25.1 million of unrestricted cash and cash equivalents, as compar...
Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update PR Newswire MARINA DEL REY, Calif. , May 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company foc...
2023-03-16 16:56:13 ET Armata Pharmaceuticals press release ( NYSE: ARMP ): Q4 GAAP EPS of -$0.29 misses by $0.01 . Revenue of $1.05M (+6.1% Y/Y) misses by $0.62M . Loss from Operations. Loss from operations for the three months ended December 31, 2022, was $...
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update PR Newswire MARINA DEL REY, Calif. , March 16, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology co...
2023-03-06 10:00:19 ET Gainers: BridgeBio Pharma ( BBIO ) +67% . Armata Pharmaceuticals ( ARMP ) +23% . TCR2 Therapeutics ( TCRR ) +21% . Euda Health ( EUDA ) +12% . Kala Pharmaceuticals ( KALA ) +16% . Losers: Aclaris...
2023-03-06 07:13:32 ET Armata Pharmaceuticals ( NYSE: ARMP ) said its inhaled bacterial infection drug for lung disorder was well-tolerated with a treatment emergent adverse event (TEAE) profile similar to placebo in a phase 1b/2a trial. The study, dubbed SWARM-P.a., ev...
News, Short Squeeze, Breakout and More Instantly...
Armata Pharmaceuticals Inc. Company Name:
ARMP Stock Symbol:
NYSE Market:
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update PR Newswire LOS ANGELES , May 7, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high...
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update PR Newswire LOS ANGELES , March 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology com...
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva PR Newswire Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 20...